Is Sequent Scien. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Sequent Scientific has moved from expensive to fair, indicating a shift in its perceived value. The company is currently fairly valued, with a PE ratio of 148.22, an EV to EBITDA ratio of 32.10, and a PEG ratio of 0.12, suggesting strong growth potential relative to its price.
In comparison to its peers, Sequent's PE ratio is significantly higher than Sun Pharma's 35.16 and Cipla's 23.63, which are both in the expensive and attractive categories, respectively. This indicates that while Sequent is fairly valued, it remains at a premium compared to some competitors. Recent stock performance shows that Sequent has outperformed the Sensex year-to-date with a return of 15.31% versus the Sensex's 7.44%, reinforcing its valuation story amidst a challenging market environment.